A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Denali Therapeutics Inc.
DNLI
$4.0B
Mkt Cap
$23.11
-1.32%
Denali Therapeutics Inc. (DNLI) has a 5-year average return on invested capital (ROIC) of -31.4%. This is below average and may indicate limited pricing power.
Denali Therapeutics Inc. (DNLI) has a market capitalization of $3.7B. It is classified as a mid-cap stock.
Denali Therapeutics Inc. (DNLI) does not currently pay a regular dividend.
Denali Therapeutics Inc. (DNLI) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Denali Therapeutics Inc. (DNLI) generated $-422 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Denali Therapeutics Inc. (DNLI) has a debt-to-equity ratio of 0.04. This indicates a conservatively financed balance sheet.
Denali Therapeutics Inc. (DNLI) reported earnings per share (EPS) of $-2.97 in its most recent fiscal year.
Table of Contents Overview and Strategy Our purpose is to bring the power of biotherapeutics to the whole body, including the brain, by discovering, developing, and delivering medicines for people living with serious diseases. Historically, the blood-brain barrier has been a major challenge to the development of medicines for diseases of the central nervous system. While the blood-brain barrier protects the brain and is essential for our survival, it also prevents the delivery of medicines to the brain in sufficient quantities to have therapeutic effect. We have invented, developed, and validated a proprietary technology, called the TransportVehicleTM ("TV"), to address the blood-brain barrier challenge and enable a new class of barrier-crossing therapeutics. The TV has a modular design enabling delivery of large molecules, i.e., enzymes, oligonucleotides, and antibodies, to all tissues of the body, including the brain, by crossing the blood-brain barrier after systemic administration.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 331M | - | - |
| Net Income | -508M | -513M | -423M | -145M | -326M | -291M |
| EPS | $-3.35 | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 |
| Free Cash Flow | -419M | -422M | -364M | -371M | -263M | -220M |
| ROIC | -34.1% | -45.5% | -37.3% | -14.0% | -32.5% | -27.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.01 | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -547M | -555M | -487M | -197M | -341M | -296M |
| Operating Margin | 0.0% | - | - | -59.5% | - | - |
| ROE | -54.9% | -45.7% | -37.4% | -14.0% | -32.5% | -27.5% |
| Shares Outstanding | 159M | 173M | 165M | 137M | 125M | 122M |
| Metric | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0 | 0 | 129M | N/A | 336M | N/A | N/A | 331M | 0 | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 76M | 74M | 143M | 193M | 213M | 265M | 359M | 424M | 396M | 419M | 406M |
| SG&A | 12M | 16M | 32M | 46M | 60M | 79M | 90M | 103M | 105M | 137M | 141M |
| EBIT | -87M | -90M | -46M | -213M | 63M | -296M | -341M | -197M | -487M | -555M | -547M |
| Op. Margin | N/A | N/A | -35.9% | N/A | 18.7% | N/A | N/A | -59.5% | N/A | N/A | 0.0% |
| Net Income | -87M | -88M | -36M | -198M | 71M | -291M | -326M | -145M | -423M | -513M | -508M |
| Net Margin | N/A | N/A | -28.1% | N/A | 21.2% | N/A | N/A | -43.9% | N/A | N/A | 0.0% |
| Non-Recurring | -3K | -1K | 36K | 0 | 0 | 0 | 0 | 0 | 15M | 0 | 0 |
| Returns on Capital | |||||||||||
| ROIC | N/M | -18.5% | -7.2% | -42.0% | 8.0% | -27.5% | -32.5% | -14.0% | -37.3% | -45.5% | -34.1% |
| ROE | 157.9% | N/A | -7.2% | -42.0% | 9.2% | -27.5% | -32.5% | -14.0% | -37.4% | -45.7% | -54.9% |
| ROA | -16257.4% | -36.2% | -6.3% | -32.5% | 6.6% | -19.3% | -22.8% | -11.1% | -33.4% | -40.7% | -40.1% |
| Cash Flow | |||||||||||
| Op. Cash Flow | -72M | -77M | 50M | -152M | 416M | -211M | -245M | -358M | -348M | -413M | -412M |
| Free Cash Flow | -78M | -80M | 47M | -169M | 413M | -220M | -263M | -371M | -364M | -422M | -419M |
| Owner Earnings | -76M | -84M | 24M | -198M | 357M | -305M | -355M | -483M | -458M | -523M | -522M |
| CapEx | 6.1M | 2.9M | 3.4M | 18M | 3.1M | 8.5M | 18M | 13M | 16M | 9.5M | 6.9M |
| Maint. CapEx | 1.5M | 3.1M | 7.4M | 8.0M | 8.5M | 8.6M | 10M | 17M | 7.8M | 11M | 12M |
| Growth CapEx | 4.7M | 0 | 0 | 9.9M | 0 | 0 | 7.5M | 0 | 8.1M | 0 | 0 |
| D&A | 1.5M | 3.1M | 7.4M | 8.0M | 8.5M | 8.6M | 10M | 17M | 7.8M | 11M | 12M |
| CapEx/OCF | N/A | N/A | 6.8% | N/A | 0.7% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 3.0M | 4.4M | 19M | 38M | 50M | 85M | 100M | 108M | 103M | 100M | 98M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||
| Net Debt | N/A | N/A | N/A | -343M | -1.4B | -801M | -1.3B | -982M | -778M | -826M | -982M |
| Cash & Equiv. | 40M | 218M | 77M | 79M | 507M | 293M | 218M | 127M | 175M | 205M | 988M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 5.6M | 5.5M | 5.5M |
| Debt/Equity | -1.01 | N/A | 0.21 | 0.18 | 0.06 | 0.07 | 0.06 | 0.05 | 0.04 | 0.04 | 0.01 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1613.7 | -771.3 | -771.3 |
| Equity | -94M | N/A | 547M | 395M | 1.2B | 962M | 1.0B | 1.0B | 1.2B | 1.0B | 926M |
| Total Assets | 533K | 487M | 662M | 553M | 1.6B | 1.4B | 1.5B | 1.2B | 1.4B | 1.1B | 1.3B |
| Total Liabilities | 95M | N/A | 115M | 158M | 454M | 442M | 418M | 123M | 144M | 131M | 340M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 36M |
| Retained Earnings | N/A | -192M | -228M | -426M | -354M | -645M | -971M | -1.1B | -1.5B | -2.1B | -2.2B |
| Working Capital | N/A | 395M | 448M | 385M | 1.4B | 519M | 1.0B | 986M | 762M | 802M | 913M |
| Current Assets | N/A | 410M | 481M | 430M | 1.5B | 897M | 1.4B | 1.1B | 864M | 901M | 1.0B |
| Current Liabilities | N/A | 14M | 33M | 45M | 72M | 378M | 364M | 78M | 102M | 98M | 110M |
| Per Share Data | |||||||||||
| EPS | -13.49 | -1.01 | -0.39 | -2.07 | 0.63 | -2.39 | -2.60 | -1.06 | -2.57 | -2.97 | -3.35 |
| Owner EPS | -11.88 | -0.96 | 0.26 | -2.07 | 3.16 | -2.51 | -2.83 | -3.52 | -2.79 | -3.03 | -3.29 |
| Book Value | -14.66 | N/A | 5.88 | 4.14 | 10.19 | 7.91 | 8.31 | 7.53 | 7.48 | 5.87 | 5.84 |
| Cash Flow/Share | -11.19 | -0.88 | 0.54 | -1.59 | 3.69 | -1.74 | -1.95 | -2.61 | -2.11 | -2.39 | -3.13 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 6.4M | 87.5M | 92.9M | 95.5M | 112.9M | 121.6M | 125.4M | 137.0M | 164.5M | 172.6M | 158.7M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | 136.1 | N/A | N/A | N/A | N/A | N/A | -6.9 |
| P/FCF | N/A | N/A | 39.5 | N/A | 23.4 | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 3.4 | 4.4 | 8.4 | 5.6 | 3.2 | 2.9 | 2.8 | 2.9 | 4.0 |
| Price/Sales | N/A | N/A | 13.3 | N/A | 11.1 | N/A | N/A | 10.5 | N/A | N/A | N/A |
| FCF Yield | N/A | -5.5% | 2.5% | -9.7% | 4.3% | -4.1% | -7.9% | -12.3% | -10.7% | -14.5% | -11.4% |
| Market Cap | N/A | 1.4B | 1.8B | 1.7B | 9.7B | 5.4B | 3.3B | 3.0B | 3.4B | 2.9B | 3.7B |
| Avg. Price | N/A | 18.14 | 18.47 | 19.77 | 33.14 | 58.60 | 30.97 | 25.22 | 22.16 | 16.12 | 23.11 |
| Year-End Price | N/A | 15.04 | 19.87 | 18.28 | 85.77 | 44.30 | 26.60 | 21.95 | 20.61 | 16.87 | 23.11 |
Denali Therapeutics Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +47.9%.
Denali Therapeutics Inc. (DNLI) has a return on equity (ROE) of -45.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for Denali Therapeutics Inc. (DNLI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Denali Therapeutics Inc. (DNLI) has a book value per share of $5.87, based on its most recent annual SEC filing.